Extemporaneous formulations in Germany – relevance for everyday clinical practice

Extemporaneous formulations broaden the spectrum of therapeutic options for topical treatment in particular and thus improve patient care. The latest amendment to the Regulation on the Operation of Pharmacies issued in 2012 brought about changes in prescribing and manufacturing practices. The aim of the present study was to assess the relevance of extemporaneous formulations in everyday clinical practice.

[1]  P. Schmid‐Grendelmeier,et al.  S2k guideline on diagnosis and treatment of atopic dermatitis — short version , 2016, Allergo Journal International.

[2]  J. Ring,et al.  ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  C. Hoffmann.  [Officinal bases and their characteristics]. , 2016, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[4]  P. Schmid‐Grendelmeier,et al.  S2k guideline on diagnosis and treatment of atopic dermatitis – short version , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[5]  T. Luger,et al.  Importance of basic therapy in psoriasis , 2015, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[6]  T. Luger,et al.  Stellenwert der Basistherapie bei Psoriasis , 2015 .

[7]  J. Wohlrab,et al.  Regulatorische Besonderheiten für Topika , 2014, Der Hautarzt.

[8]  P. Staubach.  Sinn und Unsinn der Magistralrezeptur , 2014, Der Hautarzt.

[9]  P. Staubach,et al.  Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new? , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[10]  J. Wohlrab.  Individual‐ und Magistralrezeptur , 2013 .

[11]  P. Staubach,et al.  Magistralrezeptur und Pruritustherapie – Was ist etabliert, was hat sich bewährt, was ist neu? , 2013 .

[12]  G. Wolf.  [Amendment to the pharmacy operations regulation 2012. New regulations in the field of dermatological formulations]. , 2012, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[13]  P. Staubach,et al.  [Basic or maintenance therapy in dermatology. Appropriate vehicles, possibilities and limitations]. , 2014, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[14]  J. Wohlrab,et al.  [Regulatory requirements for topical preparations]. , 2014, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[15]  P. Staubach.  [Sense and nonsense of extemporaneous formulations]. , 2014, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[16]  J. Wohlrab.  [Individualized drug compounding]. , 2013, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[17]  P. Altmeyer,et al.  [Analysis of compound prescriptions by practicing dermatologists. A study of 72,615 prescriptions for patients insured by the North Rhine-Westphalia BKK]. , 1997, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.